Our ‘hidden waiting list’ of delays in access to medicines is costing lives
An independent review of our entire drugs reimbursement system is urgently needed as patients wait far longer here for new drugs than in most of Europe
We have a problem with access to medicines, and it applies both to new, innovative drugs and also to low-value, high-volume older medicines. This is because we are either not spending enough – in the case of high-volume, low-value drugs – or not spending at all, in the case of many innovative medicines.
This is the hidden waiting list in our health service that is shortening many lives and damaging the quality of others. A ...